Trial reportBlood2018
Measurable residual disease detection by high-throughput sequencing improves risk stratification for pediatric B-ALL.
Open access · bronzeAbstract readClinical Trial
In one paragraph
Trial report in Blood, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 108 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
108citing papers in PubMed, 1 pooled it
21.1field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
108 citing papers in PubMed, 1 synthesis or guideline pooled it, 220 citations in OpenAlex.
- The emerging role of next-generation sequencing in minimal residual disease assessment in acute lymphoblastic leukemia: a systematic review of current literature.Frontiers in medicine · 2025Pooled it
- Bortezomib and vorinostat in combination with mitoxantrone, dexamethasone, and pegasparaginase during induction and reinduction for infants with acute lymphoblastic leukaemia: a multicentre single-arm phase 1/2 study.The Lancet. Haematology · 2026Trial
- Trial
- Outcomes of patients with childhood B-cell precursor acute lymphoblastic leukaemia with late bone marrow relapses: long-term follow-up of the ALLR3 open-label randomised trial.The Lancet. Haematology · 2019Trial
- Minimal residual disease by high-throughput sequencing in standard risk-favorable pediatric B-lymphoblastic leukemia.Blood advances · 2026Article
- Genomic-guided precision oncology in canine cancer: from comparative genomics to liquid biopsy and molecular monitoring.Journal of veterinary science · 2026Review
- A genomic and epigenomic lens into the biology of acute lymphoblastic leukaemia.Nature reviews. Cancer · 2026Review
- Antigen Pressure, Clonal Evolution, and Lineage Plasticity in B-Cell Acute Lymphoblastic Leukemia: Resistance Biology in the Immunotherapy Era.Current hematologic malignancy reports · 2026Review
- Non-specific Clones Hamper the Reliability of Immunoglobulin Light Chain Gene Rearrangements in Next-Generation Sequencing-Based Measurable Residual Disease Monitoring in Pediatric B-Cell Acute Lymphoblastic Leukemia: A Single-Center Cohort Study.Annals of laboratory medicine · 2026Observational
- Low flow cytometry events in detecting CNS involvement in pediatric B-cell precursor ALL: NGS validation and prognostic significance.Blood advances · 2026Article
- Interpreting next-generation immunosequencing results in children and young adults with acute lymphoblastic leukemia.Blood advances · 2026Review
- Minimal disease detection by immunoglobulin high-throughput sequencing in pediatric Burkitt lymphoma.Blood advances · 2026Article
- Review
- Ovarian tissue quality assessment and fertility preservation strategies enabled by multi-omics and artificial intelligence: current applications and clinical perspectives.Frontiers in physiology · 2026Review
- Complexities of Measurable Residual Disease Assays in Acute Lymphoblastic Leukemia: A Guide for the Practicing Clinician.Acta haematologica · 2026Review
- Immune targeting in Ph-negative and Ph-positive B-ALL: improving outcomes and minimizing chemotherapy in adult B-ALL.Hematology. American Society of Hematology. Education Program · 2025Review
- Adapting measurable residual disease evaluation to clinical practice for patients with acute lymphoblastic leukemia who underwent allogeneic stem cell transplantation.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2025Article
- A Decade of Transformation in the Management of Childhood Acute Lymphoblastic Leukemia: From Conventional Chemotherapy to Precision Medicine.Pediatric reports · 2025Review
- The genomic landscape of relapsed infant and childhood KMT2A-rearranged acute leukemia.Nature communications · 2025Article
- Article
48 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
17 authors at 12 institutions in 1 country.
Brent WoodDepartment of Laboratory Medicine, University of Washington, Seattle, WA.
David WuDepartment of Laboratory Medicine, University of Washington, Seattle, WA.
Beryl CrossleyAdaptive Biotechnologies, Seattle, WA.
Yunfeng DaiDepartment of Biostatistics, University of Florida, Gainesville, FL.
David WilliamsonAdaptive Biotechnologies, Seattle, WA.
Charles GawadOncology, St. Jude Children's Research Hospital, Memphis, TN.
Michael J BorowitzOncology, St. Jude Children's Research Hospital, Memphis, TN.
Meenakshi DevidasDepartment of Biostatistics, University of Florida, Gainesville, FL.
Kelly W MaloneyUniversity Physicians, Children's Hospital of Colorado, Aurora, CO.
Eric LarsenMaine Children's Cancer Center, Scarborough, ME.
Naomi WinickPediatric Oncology, UT Southwestern, Dallas, TX.
Elizabeth RaetzPediatric Hematology/Oncology, University of Utah, Salt Lake City, UT.
William L CarrollPediatric Oncology, New York University, New York, NY.
Stephen P HungerPediatric Hematology/Oncology, Children's Hospital of Philadelphia, Philadelphia, PA.
Mignon L LohPediatric Hematology/Oncology, University of California San Francisco, San Francisco, CA; and.
Harlan RobinsAdaptive Biotechnologies, Seattle, WA.
Ilan KirschAdaptive Biotechnologies, Seattle, WA.
Adaptive Biotechnologies (United States) · USSt. Jude Children's Research Hospital · USUniversity of Florida · USUniversity of Washington · USChildren's Hospital Colorado · USChildren's Hospital of Philadelphia · USFred Hutch Cancer Center · USNew England Cancer Specialists · USNew York Oncology Hematology · USThe University of Texas Southwestern Medical Center · USUniversity of California, San Francisco · USUniversity of Utah · US
Funding
NCTN BIQSFP ANBL1531 (NRT)U10CA180886 · NCI · PUBLIC HEALTH INSTITUTE · PI Douglas S. Hawkins · 2014 to 2026
$390.6MCOG SDMC - Statistics CoreU10CA180899 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI TODD A ALONZO · 2014 to 2026
$132.8MDeep sequencing for minimal residual disease detection in Acute Lymphoblastic LeuR01CA175353 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI ROBINS, HARLAN S., WOOD, BRENT L · 2014 to 2018
$3.1MNCI NIH HHS R01 CA175353NCI NIH HHS U10 CA180886NCI NIH HHS U10 CA180899
Abstract
Early response to induction chemotherapy is an important prognostic factor in B-lymphoblastic leukemia (B-ALL). Here, we compare high-throughput sequencing (HTS) of
Indexed as
High-Throughput Nucleotide SequencingPrecursor B-Cell Lymphoblastic Leukemia-LymphomaAdolescentChildChild, PreschoolDisease-Free SurvivalFemaleHumansInfantMaleNeoplasm, ResidualRisk AssessmentSurvival Rate
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.